Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 11,175 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 3 Clear all
Completed Phase 2 Interventional Results available

Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract

NCT03159143
View directory record Official record
Conditions
Metastatic Transitional Cell Cancer of the Urothelial Tract
Interventions
Docetaxel, Oxaliplatin
Drug
Lead sponsor
Leonard Appleman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01928576
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Epigenetic Therapy
Interventions
Azacitidine, Entinostat, Nivolumab, CC-486 300
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Not applicable Interventional Results available

Auto Control of Volume Management for Limb Loss

NCT03550118
View directory record Official record
Conditions
Lower Limb Amputation Below Knee (Injury)
Interventions
Adjustable socket
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

NCT00818662
View directory record Official record
Conditions
Alzheimer´s Disease
Interventions
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
50 Years to 89 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

NCT03197935
View directory record Official record
Conditions
Triple-negative Breast Cancer
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Not applicable Interventional Results available

Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy

NCT02000908
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
photobiomodulation, Sham treatment, Physiotherapy
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 19, 2026, 10:02 PM EDT
Not listed Not applicable Interventional

An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis

NCT03876860
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer, Vaginal Stricture, Radiation Toxicity
Interventions
Silicone Dilator, Standard Dilator
Device
Lead sponsor
Margaret Liotta
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 19, 2026, 10:02 PM EDT
Not listed Phase 1Phase 2 Interventional

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

NCT04485260
View directory record Official record
Conditions
Myelofibrosis
Interventions
KRT-232, Ruxolitinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Duarte, California • Baltimore, Maryland • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 19, 2026, 10:02 PM EDT
Not yet recruiting Not applicable Interventional

Activity Post Spinal Surgery Engagement Trial

NCT07825480
View directory record Official record
Conditions
Spinal Surgery for Lumbar Spinal Stenosis (LSS)
Interventions
Wrist based activity tracker wear, Basic Study Activities, Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Not applicable Interventional Results available

A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses

NCT02922959
View directory record Official record
Conditions
Drug Overdose, Opioid-Related Disorders, Drug Addiction, Drug Abuse, Substance Abuse
Interventions
Peer Intervention, naloxone nasal spray kit, Personally-tailored opioid overdose prevention education (information packet)
Behavioral · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

NCT02037074
View directory record Official record
Conditions
Schizophrenia
Interventions
Drug: EVP-6308, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 19, 2026, 10:02 PM EDT
Terminated Not applicable Interventional Results available

Engaging Working Memory and Distress Tolerance to Aid Smoking Cessation

NCT03565497
View directory record Official record
Conditions
Smoking Cessation
Interventions
Wellness Education Control Condition, Mindfulness Training, Mindfulness Training Plus IE
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 19, 2026, 10:02 PM EDT
Terminated No phase listed Observational

A Multi-center, International Prospective Follow up Study

NCT04579913
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound
Other
Lead sponsor
Medi-Tate Ltd.
Industry
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Pompano Beach, Florida • Manhattan, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Not applicable Interventional

Ketamine Anesthesia for Improvement of Depression in ECT

NCT02752724
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Methohexital
Drug
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Fasting Mimicking Diet

NCT04150159
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
FMD Arm
Dietary Supplement
Lead sponsor
Hypertension Institute, Nashville
Other
Eligibility
35 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity

NCT07400679
View directory record Official record
Conditions
Overweight, Obesity, Healthy
Interventions
PF-08653944
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

NCT01185340
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
20
States / cities
Garden Grove, California • Oakland, California • Temecula, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 19, 2026, 10:02 PM EDT
Recruiting Phase 2 Interventional

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

NCT00107289
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
iobenguane I 131
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Phase 2 Interventional

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

NCT00263276
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
dapagliflozin, placebo, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 79 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
111
States / cities
Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Not applicable Interventional

CIC Behavioral Economics in Children With Spina Bifida

NCT05562713
View directory record Official record
Conditions
Spina Bifida, Neurogenic Bladder
Interventions
Present Bias without Loss Aversion, Present Bias with Loss Aversion
Behavioral
Lead sponsor
Duke University
Other
Eligibility
4 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 19, 2026, 10:02 PM EDT
Recruiting Phase 2 Interventional

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

NCT06323460
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Paclitaxel, Positron Emission Tomography, Questionnaire Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

NCT01646320
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching with Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
26
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Phase 1 Interventional

Bio-equivalence Study Between SAPHRIS and Asenapine

NCT01948024
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
SAPHRIS, Asenapine
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Costa Mesa, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 19, 2026, 10:02 PM EDT
Completed Not applicable Interventional

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

NCT01410123
View directory record Official record
Conditions
Liver Diseases, Alcoholic, Alcoholism, HIV, Hepatitis C
Interventions
Integrated Stepped Care (ISC), Treatment as Usual
Other
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 19, 2026, 10:02 PM EDT